Gabriele Elbl
Keine laufenden Positionen mehr
Profil
Gabriele Elbl worked as Head-Regulatory Affairs at MorphoSys AG from 2013 to 2018.
Prior to that, she was SVP-Regulatory Affairs & Quality Control at Heidelberg Pharma AG in 2012.
She also served as Vice President-Global Regulatory Affairs at Nordic Nanovector ASA. Elbl holds a doctorate degree from Ludwig-Maximilians-Universität München.
Ehemalige bekannte Positionen von Gabriele Elbl
| Unternehmen | Position | Ende |
|---|---|---|
| MORPHOSYS AG | General Counsel | 01.10.2018 |
| THOR MEDICAL | General Counsel | - |
| HEIDELBERG PHARMA AG | General Counsel | - |
Ausbildung von Gabriele Elbl
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| HEIDELBERG PHARMA AG | Health Technology |
| MORPHOSYS AG | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
